The US-Mexico-Canada Agreement: Putting Profits Before Patients
By Maria Fabiana Jorge
In the US-Mexico-Canada Agreement (USMCA, NAFTA 2.0), the U.S. Trade Representative negotiated intellectual property provisions related to pharmaceuticals that would enshrine long and broad monopolies. This policy brief focuses primarily on the negative effects of the USMCA intellectual property provisions on access to medicines in the U.S. Such effects may be even worse for Canada and Mexico. The impact of this trade agreement goes well beyond the three countries involved as this is the first one negotiated by the Trump Administration and is likely to set a precedent for future trade agreements. A careful review of the USMCA text raises very serious concerns about the impact that this agreement would have on the generic/biosimilar industry and therefore on access to more affordable drugs throughout the world.
US Claims under Special Section 301 against China Undermine the Credibility of the WTO
By Nirmalya Syam and Dr. Carlos M. Correa
The US action to place China in the Special 301 ‘Priority Watch List’ is unjustified and in contravention to the WTO rules. The claims made against China are based on standards self-determined by the Office of the United States Trade Representative (USTR), not on international standards. This is an example of a systemic problem that requires a concerted response. WTO members should unite to firmly oppose the imposition of unilateral measures that undermine the multilateral trading system and the credibility of WTO as a ruled-based institution.
Intellectual Property in the Trans-Pacific Partnership: Increasing the Barriers for the Access to Affordable Medicines (revised)
Most free trade agreements (FTAs) signed by the United States, the European Union and the members of the European Free Trade Association (EFTA) in the last 15 years contain chapters on intellectual property rights with provisions applicable to pharmaceuticals. Such provisions considerably expand the rights recognized to pharmaceutical companies under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) established in the context of the World Trade Organization (WTO). (more…)
How Developing Countries Can Manage Intellectual Property Rights to Maximize Access to Knowledge
This book addresses the debate on access to knowledge in three parts. Part I describes some of the challenges for access to knowledge. Part II of the book provides an account of recent developments in multilateral forums. Part III of the book seeks to advance the strategic considerations that should be useful to developing countries in addressing the challenges with regard to access to knowledge. It is hoped that the analysis, conclusions and recommendations presented in this book will contribute to a better understanding of the challenges to access to knowledge and of how to frame development-oriented policies to address them. The book is intended to reach a broad set of readers: it provides guidelines for developing countries’ governments in participating in multilateral and bilateral negotiations as well as to design national IP regimes consistent with those countries’ development objectives. It may also be of value to scholars, teachers, and students whose interests cover such areas as law, economics, political economy, diplomacy, international relations and other social science fields.
